Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
20 participants
INTERVENTIONAL
2022-09-15
2024-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In a number of cases, RRMS progresses to a severe secondary neurodegenerative form. In this context, it is important to look for biomarkers that could indicate the pathogenic activity of certain immune cell subpopulations.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immune Regulation in Multiple Sclerosis: MicroRNA and Antigen-Presenting Cells
NCT01587690
miRNA Biomarkers in Multiple Sclerosis
NCT04772495
Biomarkers in Multiple Sclerosis
NCT00325988
A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis
NCT01737372
Combined Analysis of Inflammatory Biomarkers for CNS Autoimmune Diseases Diagnostic
NCT05056740
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be recruited among adult patients with RRMS coming for a follow-up consultation in the Neurology Department, Nervous System Diseases Pole, at the hôpital Pitié - Salpêtrière (Paris).
As this is a descriptive study, the recruitment of 20 participants (10 patients with relapsing-remitting MS and 10 patients with relapsing-remitting MS) should meet the objectives of this study.
A 50 ml blood sample will be obtained from each participant and several clinical data regarding their pathology will be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Untreated RRMS patients
Untreated RRMS patients with a 50 ml blood sample during their routine care
50 ml blodd sampling
50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
50 ml blodd sampling
50 ml blood sampling for genetic analysis (expression profiles of microRNAs)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female and male individuals with an f/m ratio of 2-4/1
* Individuals with RRMS according to the 2010 McDonald criteria for less than 15 years, with EDSS 1-6, in remission or relapse
* Participant's condition compatible with a maximum of 50 ml of blood collection
* Persons affiliated with a social security plan.
Exclusion Criteria
* Persons with acute and chronic infectious disease, autoimmune/inflammatory disease or cancer other than MS
* Pregnant or lactating women
* Be under guardianship,
* Be deprived of liberty by judicial or administrative decision, or be under legal protection.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Höpital La Pitié-Salpêtrière
UNKNOWN
Institut Pasteur
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frédérique Michel, PhD
Role: STUDY_DIRECTOR
Institut Pasteur
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital La Pitié - Salpêtrière
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A02983-3
Identifier Type: OTHER
Identifier Source: secondary_id
2021-044
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.